# Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age.

> **NCT05630859** · PHASE1,PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1004 (actual)

## Conditions studied

- Sexually Transmitted Diseases

## Interventions

- **BIOLOGICAL:** NgG low dose investigational vaccine
- **BIOLOGICAL:** NgG medium dose investigational vaccine
- **BIOLOGICAL:** NgG high dose investigational vaccine
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** NgG HTD investigational vaccine
- **BIOLOGICAL:** NgG below HTD investigational vaccine

## Key facts

- **NCT ID:** NCT05630859
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-28
- **Primary completion:** 2025-05-22
- **Final completion:** 2025-05-22
- **Target enrollment:** 1004 (ACTUAL)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05630859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05630859, "Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age.". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05630859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*